BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring the company’s commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.

The peptide BU, which is already fully operational, will be led by Fengping Xiao, Ph.D., who brings decades of experience to his newly created role spanning from drug discovery through development, with a focus on both small molecules and peptides.

Over the past couple of years, BioDuro has built comprehensive peptide capabilities across multiple technology platforms including its newly established DNA-encoded library (DEL) screening service, and AI-enabled design for peptides. The new BU will see the integration of BioDuro’s chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product capabilities into one specialized platform, and bring together the company’s significant cross-functional peptide expertise, dedicated resources and customized workflows to accelerate peptide drug discovery and development under one roof.

“The creation of this Peptide BU marks a pivotal milestone for BioDuro,” said Armin Spura, Ph.D., CEO of BioDuro. “Our mission is to build the most advanced peptide platform, powered by exceptional science, state-of-the-art technology, and a world-class team, to meet the growing customer demand for complex peptide therapeutics worldwide.”